Treating COVID-19-Associated Coagulopathy: Unfractionated Heparin vs LMWH
Which is more effective in treating coagulopathy in critically ill patients with COVID-19, unfractionated heparin or low-molecular-weight heparin?
Which is more effective in treating coagulopathy in critically ill patients with COVID-19, unfractionated heparin or low-molecular-weight heparin?
In an observational study, researchers compared the likelihood of delayed cranial decompression following the initiation of prophylactic unfractionated heparin vs low-molecular-weight heparin using the National Trauma Data Bank.
Researchers evaluated the sustainability of a program to guide ED site-of-care decisions regarding outpatient management of acute PE in low-risk patients.
Researchers are seeking to address the psychological impact of patients who have survived VTE.
What is the best current strategy for addressing patients with COVID-19 who are at high risk for thrombosis but are not in the ICU?
A study of patient follow-up trajectories following acute pulmonary embolism found missed opportunities for diagnosing CTEPH.
Can pulmonary rehabilitation improve outcomes in patients post-COVID-19 who are experiencing persistent and debilitating respiratory and other symptoms?
Is VTE risk unusually high in patients with COVID-19? To find out, researchers compared VTE incidence in inpatients with COVID-19 vs those with CAP.
Can antiplatelet therapy for critically ill patients with COVID-19 reduce the duration of respiratory or cardiovascular organ support?
Researchers sought to determine the underlying reasons for thrombosis risk in patients with severe COVID-19.